US private equity (PE) giant Blackstone is understood to be exploring exit options for Japan-based Ayumi Pharmaceutical Corp, in a deal that could value the specialty pharmaceutical company at at least $1 billion.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
